Chronic reduction in complex I function alters calcium signaling in SH-SY5Y neuroblastoma cells
暂无分享,去创建一个
Todd B. Sherer | James P. Bennett | T. Sherer | J. Parks | J. Bennett | Patricia A. Trimmer | Kate Borland | Janice K. Parks | Jeremy B. Tuttle | P. Trimmer | J. Tuttle | Kate Borland
[1] S. Dimauro,et al. Mitochondria1 involvement in Parkinson's disease , 1993, Neurology.
[2] C. Fall,et al. Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson's disease. , 1997, Biochimica et biophysica acta.
[3] J. Parks,et al. Abnormalities of the electron transport chain in idiopathic parkinson's disease , 1989, Annals of neurology.
[4] R. Tsien,et al. A new generation of Ca2+ indicators with greatly improved fluorescence properties. , 1985, The Journal of biological chemistry.
[5] R. Swerdlow,et al. Abnormal Mitochondrial Morphology in Sporadic Parkinson's and Alzheimer's Disease Cybrid Cell Lines , 2000, Experimental Neurology.
[6] J. Schulz,et al. Systemic administration of rotenone produces selective damage in the striatum and globus pallidus, but not in the substantia nigra , 1997, Brain Research.
[7] T. Pozzan,et al. Ca2+ Homeostasis in the Agonist-sensitive Internal Store: Functional Interactions Between Mitochondria and the ER Measured In Situ in Intact Cells , 1998, The Journal of cell biology.
[8] C. Moraes,et al. Titrating the Effects of Mitochondrial Complex I Impairment in the Cell Physiology* , 1999, The Journal of Biological Chemistry.
[9] Y. Imaizumi,et al. Possible mechanism of the potent vasoconstrictor actions of ryanodine on femoral arteries from spontaneously hypertensive rats , 1996, British journal of pharmacology.
[10] C. Fall,et al. Visualization of cyclosporin A and Ca2+-sensitive cyclical mitochondrial depolarizations in cell culture. , 1999, Biochimica et biophysica acta.
[11] D. Turnbull,et al. Respiratory chain abnormalities in skeletal muscle from patients with Parkinson's disease , 1991, Journal of the Neurological Sciences.
[12] D. Bers,et al. Oxygen-bridged Dinuclear Ruthenium Amine Complex Specifically Inhibits Ca2+ Uptake into Mitochondria in Vitroand in Situ in Single Cardiac Myocytes* , 1998, The Journal of Biological Chemistry.
[13] C. Marsden,et al. L‐Dihydroxyphenylalanine and complex I deficiency in Parkinson's disease brain , 1995, Movement disorders : official journal of the Movement Disorder Society.
[14] K. Tipton,et al. Advances in Our Understanding of the Mechanisms of the Neurotoxicity of MPTP and Related Compounds , 1993, Journal of neurochemistry.
[15] W. Nicklas,et al. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. , 1985, Life sciences.
[16] Samuel Thayer,et al. Mitochondria buffer physiological calcium loads in cultured rat dorsal root ganglion neurons , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[17] R. Helliwell,et al. Modulation of Ca2+‐activated Cl− currents in rabbit portal vein smooth muscle by an inhibitor of mitochondrial Ca2+ uptake , 1997, The Journal of physiology.
[18] M. Hoth,et al. Mitochondrial Regulation of Store-operated Calcium Signaling in T Lymphocytes , 1997, The Journal of cell biology.
[19] J. Parks,et al. Mitochondrial DNA-depleted neuroblastoma (Rho‡) cells exhibit altered calcium signaling , 2000 .
[20] T. Peng,et al. Mitochondrial dysfunction in Parkinson's disease. , 1999, Biochemical Society symposium.
[21] R. V. Sharma,et al. Altered signal transduction in vascular smooth muscle cells of spontaneously hypertensive rats. , 1992, Hypertension.
[22] D. Friel,et al. An FCCP-sensitive Ca2+ store in bullfrog sympathetic neurons and its participation in stimulus-evoked changes in [Ca2+]i , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[23] C. Arnoult,et al. Pharmacological properties of the T-type Ca2+ current of mouse spermatogenic cells. , 1998, Molecular pharmacology.
[24] R. Swerdlow,et al. Origin and functional consequences of the complex I defect in Parkinson's disease , 1996, Annals of neurology.
[25] J. Cooper,et al. Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease , 1998, Annals of neurology.
[26] K. Jellinger,et al. Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease , 1994, Neuroscience Letters.
[27] R. Benecke,et al. Electron transfer complexes I and IV of platelets are abnormal in Parkinson's disease but normal in Parkinson-plus syndromes. , 1993, Brain : a journal of neurology.
[28] B. Freedman,et al. Retrograde Ca2+ signaling in C2C12 skeletal myocytes in response to mitochondrial genetic and metabolic stress: a novel mode of inter‐organelle crosstalk , 1999, The EMBO journal.
[29] H. Reichmann,et al. Electron transport chain defects in Alzheimer's disease. , 1994, Neurology.
[30] W. Fiers,et al. Depletion of the mitochondrial electron transport abrogates the cytotoxic and gene‐inductive effects of TNF. , 1993, The EMBO journal.
[31] G. Steele,et al. Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[32] W. Tatton,et al. Mitochondria in neurodegenerative apoptosis: An opportunity for therapy? , 1998, Annals of neurology.
[33] T. Pozzan,et al. A Role for Calcium Influx in the Regulation of Mitochondrial Calcium in Endothelial Cells (*) , 1996, The Journal of Biological Chemistry.
[34] M. Graeber,et al. Regional heterogeneity of mtDNA heteroplasmy in parkinsonian brain. , 1996, Clinical neuropathology.
[35] Dean P. Jones,et al. Prevention of Apoptosis by Bcl-2: Release of Cytochrome c from Mitochondria Blocked , 1997, Science.
[36] J. Langston,et al. Permanent human parkinsonism due to 1‐methy 1–4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) , 1985, Neurology.
[37] R. Swerdlow,et al. Interaction Among Mitochondria, Mitogen‐Activated Protein Kinases, and Nuclear Factor‐κB in Cellular Models of Parkinson's Disease , 2000, Journal of neurochemistry.
[38] J. Lunardi,et al. The 49‐kDa subunit of NADH‐ubiquinone oxidoreductase (Complex I) is involved in the binding of piericidin and rotenone, two quinone‐related inhibitors , 1998, FEBS letters.
[39] Robert E. Davis,et al. Altered Calcium Homeostasis in Cells Transformed by Mitochondria from Individuals with Parkinson's Disease , 1997, Journal of neurochemistry.
[40] T. Peng,et al. Privileged access to mitochondria of calcium influx through N-methyl-D-aspartate receptors. , 1998, Molecular pharmacology.
[41] T. Smith,et al. J-aggregate formation of a carbocyanine as a quantitative fluorescent indicator of membrane potential. , 1991, Biochemistry.
[42] P. Golstein. Controlling Cell Death , 1997, Science.
[43] C. Marsden,et al. Complex I, Iron, and ferritin in Parkinson's disease substantia nigra , 1994, Annals of neurology.
[44] Isabel Llano,et al. Intracellular calcium clearance in Purkinje cell somata from rat cerebellar slices , 1998, The Journal of physiology.
[45] C. Marín,et al. Mitochondria1 respiratory chain activity in skeletal muscle from patients with Parkinson's disease , 1993, Neurology.
[46] J. Okun,et al. Three Classes of Inhibitors Share a Common Binding Domain in Mitochondrial Complex I (NADH:Ubiquinone Oxidoreductase)* , 1999, The Journal of Biological Chemistry.
[47] O. Blin,et al. Mitochondrial respiratory failure in skeletal muscle from patients with Parkinson's disease and multiple system atrophy , 1994, Journal of the Neurological Sciences.